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Purpose: The survival of retinal ganglion cells (RGCs) is a hallmark of many optic neurodegenerative diseases such as
glaucoma. YC-1, a potential anticancer drug, is known to be able to decrease the stability and protein expression of hypoxia-
inducible factor (HIF)-1α that is triggered by hypoxia and related to RGC survival. We hypothesized that YC-1 may alter
RGC cell viability through the down-regulation of HIF-1α.
Methods: Cell viability of the RGC-5 cell line was measured with a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay. Flow cytometry, a LIVE/DEAD viability assay, and high-content screening (HCS) with MKI67
(Ki-67) monoclonal antibodies were used to detect cell death and cellular proliferation.
Results: We found that cells treated with 20 µM YC-1 for 24 h decreased the HIF-1α level in an RGC-5 cell line using
immunoblotting and reduced the live cell number in an MTT assay. Results of flow cytometry and HCS demonstrated
that reducing the cell proliferation of RGC-5 cells, not cell death, led to the decreased level in the MTT assay.
Conclusions:  Our  findings  demonstrate  that  YC-1-induced  down-regulation  of  HIF-1α  might  reduce  RGC  cell
proliferation and viability under normoxia, which implies a role of YC-1 in the neuroprotective effect for further clinical
applications.
The  retina  is  composed  of  seven  main  cell  types,
including retinal ganglion cells (RGCs), the only projection
neurons that connect to the midbrain from photoreceptor cells
[1]. RGCs can extend their axons through the optic nerve, the
optic chiasm, and the optic tract into the superior colliculus
and lateral geniculate nucleus, mainly on the contralateral side
of the brain [1]. Loss of RGCs occurs in many ophthalmic
conditions, such as glaucoma, diabetic optic neuropathy, etc.,
resulting from the process of cell apoptosis [2]. In animal
models  (monkeys  and  rabbits)  of  an  axotomy  and
experimental glaucoma, it has been shown that RGCs possibly
undergo apoptosis similar to the pathological changes that
occur  in  glaucoma,  and  diabetic  optic  neuropathy  [3-5],
neurodegenerative  diseases  [6],  anterior  ischemic  optic
neuropathy, optic neuritis, optic nerve trauma, and AIDS [7].
There are several stimuli that may initiate apoptosis and
result in the death of RGCs, such as neurotrophin deprivation,
glial activation, excitotoxicity, ischemia, and oxidative stress
[8].  These  stimuli  can  also  be  triggered  by  an  elevated
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intraocular pressure (IOP), which results in the release of
neurotoxic factors, such as nitric oxide and tumor necrosis
factor-α from retinal cells [9], a pressure-induced distortion
of the lamina cribrosa leading to shearing and compressive
forces  on  the  RGC  axons  [10],  or  compression  of  the
capillaries supplying the optic nerve head [11,12]. In these
situations, hypoxia-inducible factor (HIF)-1α can be induced
and expressed in RGCs to counter these stresses [2,13].
HIF-1α is a component of the transcription factor, HIF-1,
and is triggered by hypoxic conditions [14]. The effects of
HIF-1α  on  the  expressions  of  many  downstream  genes,
especially  those  involved  in  cell-cycle  control  and  cell
proliferation  and  death,  are  well  established  [15,16].
Moreover,  HIF-1α  stabilizers,  such  as  cobalt  chloride
(CoCl2), are able to mimic hypoxia and are used in RGC
programmed cell death models [17-20]. They are also able to
induce the expression of β-amyloid precursor protein (APP)
in  RGCs  as  well  as  hypoxia  [21],  and  they  specifically
upregulate Hsp27 after retinal ischemic preconditioning and
prevent retinal ischemic damage both in vitro (RGC-5 cell
line) and in vivo (rat retina) through HIF-1α activation [22].
These studies suggest that HIF-1α may play a key role in
preventing hypoxia-induced RGC injury.
YC-1  (3-(50-Hydroxymethyl-20-furyl)-1-benzyl
indazole)  is  a  chemically  synthetic  benzyl  indazole  that
directly activates soluble guanylate cyclase (sGC) to elevate
cyclic  (c)GMP  levels  in  rabbit  platelets  and  possesses
antiplatelet activity [23]. Recently, it was found to be able to
suppress HIF-1α expression in Hep3B cells and was suggested
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1594as a novel HIF-1α inhibitor [24]. Therefore, YC-1 is expected
to become the first antiangiogenic anticancer agent to target
HIF-1α,  as  it  was  found  to  halt  tumor  growth  in
immunodeficient mice grafted with five types of human tumor
cells [25]. Yeo et al. [15] suggested YC-1 as a good lead
compound  for  developing  novel  antiangiogenic  and
anticancer agents.
Due to the importance of HIF-1α in RGC programmed
cell death and its downstream regulation of cell survival, we
hypothesize that YC-1 might reduce HIF-1α expression and
affect RGC cell viability. We first investigated the effect of
YC-1 on HIF-1α protein expression in the RGC-5 cell line
under normoxia. Then, cell viability, cell death, apoptosis, and
proliferation were explored.
METHODS
Cell  culture:  The  RGC-5  cell  line  was  purchased  from
American Type Culture Collection (Manassas, VA). Cells
were cultured in medium composed of Dulbecco’s modified
Eagle’s  medium  (Invitrogen  Life  Technologies,  Carlsbad,
CA)  containing  4.5  g/l  D-glucose,  2.5  mM  L-glutamine,
110 mg/l sodium pyruvate, 100 U/ml penicillin/streptomycin
(Invitrogen Life Technologies), 0.125 mg/l amphotericin B
(Invitrogen Life Technologies), and 5% heat-inactivated fetal
calf serum (Invitrogen Life Technologies) in a humidified
incubator with 5% CO2 at 37 °C. The passage of RGCs used
TrypLE (Invitrogen Life Technologies) following removal of
the enzymes after centrifugation at 112× g for 5 min. Cells
were not used until they had reached 80% confluence in our
experiments.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl  tetrazolium
bromide (MTT) assay: In our experiment, cell viability was
determined by an MTT assay (Sigma-Aldrich, St. Louis, MO).
The powder was dissolved at 5 mg/ml into distilled H2O and
sterilized through a 0.22-µm filter before use. RGC cells were
seeded  in  a  96-well  plate  (5,000  cells/well,  total  100  µl)
overnight.  Then,  cells  were  treated  with  different
concentrations  of  YC-1  (Sigma-Aldrich)  in  dimethyl
sulfoxide (DMSO; Sigma-Aldrich). After treatment, 10 µl of
the MTT stock solution was added to each well and incubated
with 5% CO2 at 37 °C for 2 h. Finally, we removed the
medium, added 200 µl DMSO to each well, and incubated at
room temperature for 15 min. The absorbance was measured
at  570  nm  on  a  microplate  reader.  All  experiments  were
performed in four wells and repeated three times.
Imaging:  Photographic  images  were  captured  by  a  Zeiss
Axiovert 35 Inverted Fluorescence Microscope (Carl Zeiss,
Oberkochen, Germany) equipped with an Imaging Source
DBK  41AU02.AS  digital  camera  (Stuttgart,  Germany).
Fluorescence  microscopy  used  a  Leica  DM  2500
stereomicroscope (Wetzlar, Germany) equipped with a Leica
DFC490 digital camera. After treatment, cells were incubated
with a LIVE/DEAD® Viability/Cytotoxicity Kit (calcein AM/
ethidium homodimer-1; Molecular Probes, Eugene, OR) and
Hoechst 33342 (Invitrogen Life Technologies) for 30 min at
room temperature.
Flow cytometry: Treated cells were re-suspended in TrypLE
followed by removal of the enzymes by centrifugation (112×
g for 5 min). After filtration with a 0.45-µm filter, we counted
the number of cells and diluted the suspension to 5×106 cells/
ml.  Then,  cells  were  incubated  with  a  LIVE/DEAD®
Viability/Cytotoxicity Kit for 30 min or annexin V conjugated
to  allophycocyanin  (APC;  Invitrogen  Life  Technologies)/
propidium iodide (PI; Sigma-Aldrich) for 15 min at room
temperature. Finally, cells were analyzed by BD LSR II and
FACSCalibur flow cytometry (Becton Dickinson, San Jose,
CA).
High-content screening (HCS): We seeded RGC-5 cells in a
Costar®  96-well  black  solid  plate  (5,000  cells/well,  total
100 µl; Bio-Rad Laboratories, Hercules, CA) using a BioTek
MicroFill  Microplate  Dispenser  (BioTek  Instruments,
Winooski, VT). After treatment, cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS, pH 7.4;
Invitrogen Life Technologies) for 15 min and allowed to stand
with 0.2% Triton-X in PBS for 15 min. After washing with
PBS twice, cells were blocked with 5% BSA (BSA) in PBS
for 1 h, followed by incubation with the NCL-L-Ki67-MM1
primary antibody (1:200; Novocastra Lab, Newcastle upon
Tyne,  UK)  for  1.5  h  and  the  secondary  antibody,  Alexa
Fluor® 488 goat anti-mouse immunoglobulin G (IgG; 1:200;
Invitrogen Life Technologies), for 1 h. Finally, our sample
was  analyzed  using  a  Thermo  Scientific  Cellomics®
ArrayScan®  VTI  HCS  Reader  (Thermo  Fisher  Scientific,
Pittsburgh, PA), and the imaging output used the software
Figure 1. YC-1 decreased hypoxia-inducible factor (HIF)-1α protein
expression  in  RGC-5  cells.  Total  proteins  were  extracted  from
RGC-5  cells  treated  with  20  µM  YC-1  for  4  h.  Expressions  of
HIF-1α and β-actin were determined by western blotting. β-actin was
used as the internal control.
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(PerkinElmer, Columbus, OH).
Western blotting: Cells were washed with PBS twice, and the
total  protein  was  extracted  using  ice-cold  lysis  buffer
composed of 10% RIPA (Sigma-Aldrich) and a proteinase
inhibitor  cocktail  (Sigma-Aldrich).  After  centrifugation  at
18,994× g and 4 °C for 30 min, the protein concentration was
determined  using  an  R-250  Protein  Assay  kit  (Bio-Rad
Laboratories, Philadelphia, PA). Samples were mixed with 5×
sample buffer (312.5 mM Tris-base, 50% glycerol, 12.5% β-
mercaptoethanol, 10% sodium dodecyl sulfate [SDS], and
0.01% bromophenol blue) and dry-heated to 95 °C for 5 min
before SDS–PAGE (PAGE) with an 8% acrylamide gel. The
separated  proteins  were  transferred  onto  polyvinylidene
difluoride  (PVDF)  membranes  and  blocked  with  PBS
containing 5% non-fat milk overnight. The membranes were
incubated with the primary antibodies, an anti-rabbit HIF-1α
antibody  (1:1000;  Epitomics,  Burlingame,  CA)  and  anti-
mouse-β-actin antibody (1:104; Millipore, Bedford, MA), at
room temperature for 2 h. After washing with TBST (25 mM
Tris, 150 mM NaCl, 2 mM KCl, and 0.1% Tween-20; pH 7.4)
for 5 min three times, the membranes were incubated with an
anti-rabbit or anti-mouse horseradish peroxidase-conjugated
secondary antibody (1:104; Santa Cruz Biotechnology, Santa
Cruz, CA) at room temperature for 1 h and washed with TBST
three times. Finally, immunoblotting was visualized using an
enhanced chemiluminescence detection kit (Millipore).
Statistical  analysis:  Our  data  are  presented  as  the  mean
±standard  deviation  (SD).  The  statistical  significance  of
differences between groups was determined using Student’s
t-test. A p value of <0.05 indicated a statistically significant
difference.
RESULTS
Effect of YC-1 on HIF-1α expression in RGC-5 cells: The
effects  of  YC-1  on  the  protein  synthesis  and  stability  of
HIF-1α are well established in vivo and in vitro [24,26-28].
Here,  in  RGC-5  cells,  we  also  demonstrated  that  YC-1
similarly decreased HIF-1α expression by western blotting
(Figure 1).
Effect of YC-1 on RGC-5 cell viability: MTT is a formazan
dye that is reduced enzymatically by involvement with NADH
or NADPH in live cells [29,30]. An MTT assay is commonly
used to estimate cell survival, growth, and differentiation in
response to extracellular activators or toxic agents [31]. We
used an MTT assay to measure changes in the number of live
RGC-5 cells after being exposed to YC-1. Our results revealed
that the absorbance at 570 nm in the MTT assay displayed a
dose- and time-dependent response after RGC-5 cells were
exposed to YC-1 (Figure 2B and Figure 3B). Exposure to low
concentrations of YC-1 did not induce RGC-5 death until
>20 µM (Figure 2B). Cells treated with 20 µM YC-1 for 24 h
exhibited ~30% reduced cell viability compared to the control
group. Short-term incubation (4 and 12 h) of RGC-5 with
Figure 2. YC-1 induced dose-dependent retinal ganglion cell (RGC) cell death. A: RGC-5 cells were exposed to 5, 10, 20, and 40 µM YC-1
and 0.066% DMSO for 24 h. Morphological changes in cell density were observed with light microscopy. B: Cell viability was detected with
an MTT assay of increasing the YC-1 concentration to treat RGC-5 cells. * Indicates p<0.05 compared to the DMSO vehicle group.
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in an insignificant increase in the cell number (Figure 3B).
Morphological  results  also  showed  that  YC-1  indeed
decreased the cell density of RGC-5 cells (Figure 2A and
Figure 3A). These findings established that YC-1 actually
reduced the number of live cells.
Effect of YC-1 on the number of apoptotic RGC-5 cells: The
MTT assay is widely used in cytotoxicity and cell proliferation
screening.  We  hypothesized  two  possible  reasons  for  the
decreased absorbance of MTT after YC-1 exposure: induction
of cytotoxicity and inhibition of cell proliferation. We first
analyzed  the  cytotoxicity  of  YC-1  using  calcein  AM  and
EthD-1 dyes, respectively, to determine the number of live
and dead cells. The non-fluorescent calcein AM is known to
be cell permeable, and it converts to the intensely fluorescent
calcein by intracellular esterase in live cells and then emits
green  fluorescence.  When  EthD-1  binds  nucleic  acids,  it
undergoes a 40-fold enhancement in fluorescence. However,
EthD-1 can be excluded by the intact plasma membranes of
live cells, but it presents a bright-red fluorescence in dead
cells. Our findings demonstrated that YC-1 decreased the
density of live cells but did not significantly increase the
density of dead cells compared to the control group (Figure
4A), as was also found by flow cytometry (Figure 4B). This
indicates that YC-1 should be a noncytotoxic agent toward
RGCs.
To confirm these findings, we further used annexin V and
a fluorescent nucleic acid dye, PI, with flow cytometry to
differentiate  apoptotic  and  necrotic  cells.  Annexin  V  is  a
calcium-dependent  protein  probe  that  detects  an  early
apoptotic marker, phosphatidylserine, on cell surfaces [32].
Our data indicated that YC-1 did not significantly change the
ratio of apoptotic and necrotic cells (Figures 5A,B). Taken
together,  we  determined  that  YC-1  suppressed  RGC-5
survival  but  did  not  induce  programmed  cell  death.
Accordingly, we inferred that YC-1 may decrease the number
of live cells by inhibiting cell proliferation and consequently
result in the decreased absorbance of MTT.
Effect of YC-1 on RGC-5 cell proliferation: Ki-67 is a nuclear
protein and a proliferation marker that exists in all periods of
the cell cycle except the resting stage (G0) [33]. To further
clarify the role of YC-1 in cell proliferation, we used HCS to
detect nuclear Ki-67 expression after YC-1 treatment. HCS is
an  efficient  technique  that  is  combined  with  numerous
hardware improvements and quantitative measurements of
cellular  imaging  to  collect  data  from  complex  biologic
systems [34]. Results showed that YC-1 markedly reduced the
density  of  MKI67  (Ki-67)  expression  (Figure  6A).  Ki-67
expression in the nuclei of cells treated with 20 µM YC-1 for
24 h decreased ~15% compared to that of the control group
(Figure  6B).  Our  findings  confirmed  that  YC-1-induced
RGC-5 loss was independent of cell death and apoptosis but
Figure 3. An increase of the YC-1 exposure time resulted in a decrease of the RGC-5 cell density. A: RGC-5 cells were exposed to 20 µM
YC-1 for 4, 12, and 24 h. Morphological changes in cell density were observed with light microscopy. B: Cell viability was detected by an
MTT assay of RGC-5 cells treated with YC-1 for different incubation times. * Indicates p<0.05 compared to the DMSO vehicle group.
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inhibition of cell proliferation.
DISCUSSION
The  present  study  explored  the  inhibitory  effect  of  YC-1
targeting HIF-1α on RGC-5 survival under normoxia. We
found that YC-1 directly attenuated HIF-1α expression and
subsequently decreased the number of live cells, according to
an MTT assay. However, YC-1 significantly lowered RGC-5
cell  viability  but  had  little  to  no  influence  on  dead  and
apoptotic cells using flow cytometric measurements of calcein
AM/EthD-1 and annexin V/PI fluorescent staining. The HCS
results showed that the decrease in live cells was likely due to
a reduction in cell proliferation. Our results indicated that
YC-1 should be noncytotoxic in vitro, although it interfered
with RGC-5 survival.
HIF-1α  was  stabilized  under  hypoxia  but  rapidly
degraded in normoxic conditions [35]. Many studies have
Figure 4. YC-1 had no influence on RGC-5 cell death. A: After treatment with 20 µM YC-1 or 0.066% DMSO for 24 h, RGC-5 cells were
stained with calcein AM (green for live cells), EthD-1 (red for dead cells), and Hoechst 33342 (blue for nuclei) for 40 min at room temperature.
Representative photomicrographs show the cell density and composition. B: Cell viability was examined by calcein AM/EthD-1 fluorescence
staining and flow cytometry.
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1598Figure 5. There was no significant increase of apoptotic RGC-5 cells after treatment with YC-1. A: RGC-5 cells were treated with 20 µM
YC-1 or 0.066% DMSO for 24 h. Apoptosis of cells was assessed using annexin V/propidium iodide staining and flow cytometry. B: The
histogram shows the representative flow cytometry data of three experiments.
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have discussed its role under normoxia. It is well established
that YC-1 can act on the response domain of HIF-1α and
promote  HIF-1  degradation  [26-28].  Our  immunoblotting
results showed that YC-1 attenuated the HIF-1α protein level
in RGC-5 cells under normoxia. The findings suggest that
HIF-1α  is  physiologically  required  to  maintain  RGC  cell
survival.
HIF-1 is a heterodimeric protein composed of HIF-1α and
HIF-1β subunits. The HIF transcription system can act as a
key regulator of responses to changes in oxygen levels and
activates  more  than  70  genes  that  provide  adaptation  to
ischemia and oxidative stress [35,36]. HIF-1 has also been
mentioned  as  a  potential  medicinal  target  for
neurodegenerative diseases, like Alzheimer, Parkinson, and
Huntington’s diseases and amyotrophic lateral sclerosis [37].
In  this  article,  we  demonstrated  a  correlation  between
HIF-1α  levels  and  RGC  viability.  We  inferred  that  the
neuroprotective  role  of  HIF-1α  may  regulate  downstream
genes  involved  in  RGC  growth  and  proliferation  under
normoxia.
Many studies have examined the mechanisms of YC-1-
inhibited cell proliferation. Tulis et al. suggested that YC-1
inhibited  cell  proliferation  through  a  cGMP-dependent
mechanism in rat vascular smooth muscle cells (VSMCs)
[38].  In  contrast,  other  studies  have  reported  that  the
mechanism was cGMP-independent in human umbilical vein
endothelial  cells  [39],  primary  rat  thoracic  aorta  VSMCs
[40], HA22T and Hep3B cells [41], and rat mesangial cells
[42]. Furthermore, it has been reported that YC-1 induced S-
phase arrest under hypoxia via an HIF-1α-related pathway in
Hep3B,  HEK293,  and  Caki-1  cells  [43].  This  finding
corresponds with our hypothesis and provides evidence of
HIF-1α-regulated RGC survival.
The  loss  of  RGCs  is  an  important  characteristic  of
glaucoma  and  diabetic  eye  disease  [3-5],  which  has  been
implicated  by  the  results  of  hypoxia  [2,44-46].  The
vulnerability of RGC loss might result from its sensitivity to
acute,  transient,  and  even  mildly  systemic  hypoxic  stress
[47].  In  this  study,  we  demonstrated  that  inhibition  of
HIF-1α  protein  expression  results  in  a  decrease  of  RGC
viability.  Our  results  indicated  that  HIF-1α  could  be  a
potential target able to control the progress of RGC survival-
related eye disease and a crucial target for drug development
in treatments of cancer, heart disease, and stroke [48].
As YC-1 is able to reduce RGC viability without inducing
cell death, we think that YC-1 should be independent of RGC
survival-related  optic  pathologies.  Recently,  Song  et  al.
established that YC-1 can inhibit HIF-1 expression and laser-
induced choroidal neovascularization in rats [49]. On the other
hand,  YC-1  was  found  to  suppress  pathological  retinal
neovascularization  and  enhance  physiologic
revascularization of the retinal vascular plexuses in a mouse
with oxygen-induced retinopathy by impairing the ischemia-
Figure  6.  YC-1  reduced  RGC-5  cell
proliferation.  A:  YC-1  decreased  the
number  of  nuclei  and  the  Ki-67  cell
proliferation  marker  expression  in
RGC-5  cells  using  Cellomics®  high-
content screening and the Columbus™
system. RGC-5 cells were treated with
5, 10, 20, and 40 µM YC-1 or 0.066%
DMSO  for  24  h.  After  fixation  and
immunofluorescence  staining,  cells
were detected and analyzed by an HCS
reader.  Photos  show  fluorescence
staining results of Hoechst 33342 (blue)
and Ki-67 (green). B: The quantification
results  of  HCS.  *  Indicates  p<0.05
compared to the Hoechst-stained nuclei
of the DMSO vehicle group. # Indicates
p<0.05 compared to the Ki-67-stained
cells of the DMSO vehicle group.
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1600induced expression of HIF-1 and its downstream angiogenic
molecules [50]. Moreover, YC-1 was shown to elevate the
IOP  in  rabbits  [51]  and  decrease  the  human  trabecular
meshwork cell volume [52]. Evidently, the definite effects of
YC-1 on ocular development and progressive eye diseases
need to be clarified.
Our  findings  demonstrate  that  YC-1  can  reduce  the
viability of RGCs and inhibit cell proliferation. These results
may cause down-regulation of the HIF-1α signal pathway.
Nevertheless,  HIF-1α  has  been  reported  to  possess  the
essential ability to cause arrest of the cell cycle during hypoxia
[53]. This suggests the possibility that YC-1 affects RGC cell
proliferation in hypoxic conditions. The relationship between
HIF-1α  and  RGC  survival  under  normoxia  and  hypoxia
should be further discussed in the future.
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